Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.45 |
| ▸ | PPARA | Q07869 | 2/20 | 0.45 |
| ▸ | NAAA | Q02083 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27583131 | 0.91 | L3MBTL1 (0.64) | LMNAL3MBTL1MAPTCYP1A2GAA | |
| SCHEMBL3813646 | 0.91 | L3MBTL1 (0.64) | LMNAL3MBTL1MAPTCYP1A2GAA | |
| SCHEMBL10472516 | 0.91 | L3MBTL1 (0.64) | LMNAL3MBTL1MAPTCYP1A2GAA | |
| SCHEMBL1968848 | 0.86 | NAAA (0.48) | MAPTNAAACYP1A2GAACYP2C9 | |
| SCHEMBL2221132 | 0.86 | NAAA (0.48) | MAPTNAAACYP1A2GAACYP2C9 | |
| SCHEMBL3260466 | 0.84 | GAA (0.57) | LMNAPPARGPPARACYP1A2GAA | |
| SCHEMBL1973572 | 0.84 | GAA (0.57) | LMNAPPARGPPARACYP1A2GAA | |
| SCHEMBL1968068 | 0.81 | PPARG (0.47) | LMNAMAPTPPARGPPARANAAA | |
| SCHEMBL12437213 | 0.81 | PPARG (0.47) | LMNAMAPTPPARGPPARANAAA | |
| SCHEMBL1902133 | 0.81 | LMNA (0.47) | LMNAL3MBTL1MAPTPPARGCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340493-B2 | Hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340493-B2 | Hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340493-B2 | Hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20140206651-A1 | Hydroxamic Acid Derivatives Useful As Antibacterial Agents | PFIZER INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206651-A1 | Hydroxamic Acid Derivatives Useful As Antibacterial Agents | PFIZER INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206651-A1 | Hydroxamic Acid Derivatives Useful As Antibacterial Agents | PFIZER INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-8722686-B2 | Hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722686-B2 | Hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722686-B2 | Hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-20110178042-A1 | Hydroxamic Acid Derivatives Useful as Antibacterial Agents | PFIZER INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178042-A1 | Hydroxamic Acid Derivatives Useful as Antibacterial Agents | PFIZER INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178042-A1 | Hydroxamic Acid Derivatives Useful as Antibacterial Agents | PFIZER INC. (US) | 2011-07-21 | — | — | US | disclosed |
| EP-2334636-A2 | HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | Pfizer Inc. (US) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010032147-A2 | HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206651-A1 | Hydroxamic Acid Derivatives Useful As Antibacterial Agents | HCAR1, H1-0, HDAC1 | LMNA 1822/4885L3MBTL1 208/4885MAPT 4467/4885 |
| US-20110178042-A1 | Hydroxamic Acid Derivatives Useful as Antibacterial Agents | HCAR1, HDAC1, H1-0 | LMNA 1435/4885L3MBTL1 141/4885MAPT 4466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.